Program Goals Program Outline History of Carcinoid Tumors Features of NETs Incidence of NETs Over Time by Primary Site Are NETs Really That Rare Patient Characteristics That Affect Treatment Selection ID: 677176
Download Presentation The PPT/PDF document "ESSENTIAL CONCEPTS IN THE USE OF SOMATOS..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
ESSENTIAL CONCEPTS IN THE USE OF SOMATOSTATIN ANALOGUES IN PATIENTS WITH NEUROENDOCRINE TUMORSSlide2
Program GoalsSlide3
Program OutlineSlide4
History of Carcinoid TumorsSlide5
Features of NETsSlide6Slide7
Incidence of NETs Over Time by Primary SiteSlide8
Are NETs Really That "Rare"?Slide9
Patient Characteristics That Affect Treatment SelectionSlide10Slide11Slide12
Pathology (Ki-67)Slide13
Other Classification and Nomenclature SystemsSlide14Slide15Slide16
Treatment Characteristics that Affect Treatment Selection (cont)Slide17
SSAs May Play Various Roles in the NET Treatment AlgorithmSlide18
SSAs Are Mainstay of Treatment for Controlling HormonesSlide19
SSAs Also Have a Role in Controlling Tumor GrowthSlide20
Physiology of Somatostatin and SSAsSlide21
Tools Used for Hormone ControlSlide22
ELECT Trial: Randomized Trial of Lanreotide for Carcinoid SyndromeSlide23
General Principles of SSA Dosing For Hormone ControlSlide24
Tools for Tumor Control in NETsSlide25
PROMID: Octreotide LAR for Tumor Control in Metastatic Midgut NETs Slide26
CLARINET: Antitumor Effects of Lanreotide in Metastatic NETsSlide27
Key Features of PROMID vs CLARINETSlide28
Principles of SSA Dosing For Tumor ControlSlide29
COOPERATE-2: Everolimus ± Pasireotide in Advanced Pancreatic NETsSlide30
Peptide Receptor Radionuclide TherapySlide31
NETTER-1: Peptide Receptor Radionuclide TherapySlide32
ConclusionsSlide33
AbbreviationsSlide34
Abbreviations (cont)Slide35
Abbreviations (cont)Slide36
Abbreviations (cont)Slide37
ReferencesSlide38
References (cont)Slide39
References (cont)Slide40
References (cont)Slide41
References (cont)Slide42
References (cont)Slide43
References (cont)